nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ESR1—urinary bladder cancer	0.458	1	CbGaD
Naloxone—ABCB1—Mitomycin—urinary bladder cancer	0.062	0.22	CbGbCtD
Naloxone—SLCO1A2—Methotrexate—urinary bladder cancer	0.0312	0.111	CbGbCtD
Naloxone—ALB—Fluorouracil—urinary bladder cancer	0.0292	0.104	CbGbCtD
Naloxone—CYP3A4—Thiotepa—urinary bladder cancer	0.0282	0.1	CbGbCtD
Naloxone—CYP2C8—Fluorouracil—urinary bladder cancer	0.0226	0.0801	CbGbCtD
Naloxone—CYP2C8—Etoposide—urinary bladder cancer	0.0188	0.0669	CbGbCtD
Naloxone—ABCB1—Gemcitabine—urinary bladder cancer	0.0179	0.0634	CbGbCtD
Naloxone—ALB—Methotrexate—urinary bladder cancer	0.0161	0.0572	CbGbCtD
Naloxone—ABCB1—Cisplatin—urinary bladder cancer	0.013	0.0461	CbGbCtD
Naloxone—ABCB1—Etoposide—urinary bladder cancer	0.0127	0.0453	CbGbCtD
Naloxone—ABCB1—Doxorubicin—urinary bladder cancer	0.00869	0.0309	CbGbCtD
Naloxone—ABCB1—Methotrexate—urinary bladder cancer	0.00842	0.0299	CbGbCtD
Naloxone—TLR4—prostate gland—urinary bladder cancer	0.00765	0.158	CbGeAlD
Naloxone—CYP3A4—Etoposide—urinary bladder cancer	0.00764	0.0271	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—urinary bladder cancer	0.00521	0.0185	CbGbCtD
Naloxone—CREB1—prostate gland—urinary bladder cancer	0.00337	0.0697	CbGeAlD
Naloxone—OPRK1—prostate gland—urinary bladder cancer	0.00255	0.0528	CbGeAlD
Naloxone—CREB1—epithelium—urinary bladder cancer	0.00248	0.0512	CbGeAlD
Naloxone—TLR4—lymph node—urinary bladder cancer	0.00244	0.0505	CbGeAlD
Naloxone—CREB1—smooth muscle tissue—urinary bladder cancer	0.00238	0.0493	CbGeAlD
Naloxone—CREB1—renal system—urinary bladder cancer	0.0023	0.0475	CbGeAlD
Naloxone—CREB1—urethra—urinary bladder cancer	0.00226	0.0466	CbGeAlD
Naloxone—CYP3A4—urine—urinary bladder cancer	0.00206	0.0426	CbGeAlD
Naloxone—Shivering—Gemcitabine—urinary bladder cancer	0.00196	0.0304	CcSEcCtD
Naloxone—CREB1—female reproductive system—urinary bladder cancer	0.00184	0.038	CbGeAlD
Naloxone—OPRD1—renal system—urinary bladder cancer	0.00181	0.0375	CbGeAlD
Naloxone—Irritability—Valrubicin—urinary bladder cancer	0.00174	0.0269	CcSEcCtD
Naloxone—Injection site reaction—Mitomycin—urinary bladder cancer	0.00172	0.0266	CcSEcCtD
Naloxone—CREB1—vagina—urinary bladder cancer	0.00166	0.0344	CbGeAlD
Naloxone—Pulmonary oedema—Mitomycin—urinary bladder cancer	0.00154	0.0238	CcSEcCtD
Naloxone—Morphine—UGT2B7—urinary bladder cancer	0.00153	1	CrCbGaD
Naloxone—OPRK1—female reproductive system—urinary bladder cancer	0.00139	0.0288	CbGeAlD
Naloxone—Encephalopathy—Thiotepa—urinary bladder cancer	0.00135	0.021	CcSEcCtD
Naloxone—ESR1—prostate gland—urinary bladder cancer	0.00133	0.0274	CbGeAlD
Naloxone—Encephalopathy—Fluorouracil—urinary bladder cancer	0.00112	0.0173	CcSEcCtD
Naloxone—CREB1—lymph node—urinary bladder cancer	0.00108	0.0222	CbGeAlD
Naloxone—SLCO1A2—renal system—urinary bladder cancer	0.00107	0.022	CbGeAlD
Naloxone—ESR1—epithelium—urinary bladder cancer	0.000974	0.0202	CbGeAlD
Naloxone—ESR1—smooth muscle tissue—urinary bladder cancer	0.000939	0.0194	CbGeAlD
Naloxone—ESR1—renal system—urinary bladder cancer	0.000904	0.0187	CbGeAlD
Naloxone—Rhinorrhoea—Cisplatin—urinary bladder cancer	0.00084	0.013	CcSEcCtD
Naloxone—Pulmonary oedema—Thiotepa—urinary bladder cancer	0.000773	0.012	CcSEcCtD
Naloxone—CYP2C8—renal system—urinary bladder cancer	0.000744	0.0154	CbGeAlD
Naloxone—Injection site reaction—Gemcitabine—urinary bladder cancer	0.000726	0.0113	CcSEcCtD
Naloxone—ESR1—female reproductive system—urinary bladder cancer	0.000724	0.015	CbGeAlD
Naloxone—Pain—Carboplatin—urinary bladder cancer	0.000708	0.011	CcSEcCtD
Naloxone—Abdominal pain—Valrubicin—urinary bladder cancer	0.000707	0.011	CcSEcCtD
Naloxone—Body temperature increased—Valrubicin—urinary bladder cancer	0.000707	0.011	CcSEcCtD
Naloxone—Coma—Fluorouracil—urinary bladder cancer	0.000656	0.0102	CcSEcCtD
Naloxone—ESR1—vagina—urinary bladder cancer	0.000655	0.0135	CbGeAlD
Naloxone—Body temperature increased—Carboplatin—urinary bladder cancer	0.000654	0.0101	CcSEcCtD
Naloxone—Hypertension—Mitomycin—urinary bladder cancer	0.000651	0.0101	CcSEcCtD
Naloxone—Pulmonary oedema—Gemcitabine—urinary bladder cancer	0.00065	0.0101	CcSEcCtD
Naloxone—Asthenia—Valrubicin—urinary bladder cancer	0.000641	0.00994	CcSEcCtD
Naloxone—Diarrhoea—Valrubicin—urinary bladder cancer	0.000612	0.00948	CcSEcCtD
Naloxone—Cardiac arrest—Thiotepa—urinary bladder cancer	0.000599	0.00929	CcSEcCtD
Naloxone—CYP2C8—female reproductive system—urinary bladder cancer	0.000596	0.0123	CbGeAlD
Naloxone—Encephalopathy—Methotrexate—urinary bladder cancer	0.000582	0.00902	CcSEcCtD
Naloxone—Vomiting—Valrubicin—urinary bladder cancer	0.000568	0.00881	CcSEcCtD
Naloxone—Dyspnoea—Mitomycin—urinary bladder cancer	0.000549	0.00851	CcSEcCtD
Naloxone—CYP2C8—vagina—urinary bladder cancer	0.000539	0.0112	CbGeAlD
Naloxone—Nausea—Valrubicin—urinary bladder cancer	0.000531	0.00823	CcSEcCtD
Naloxone—Pain—Mitomycin—urinary bladder cancer	0.000527	0.00816	CcSEcCtD
Naloxone—ABCB1—prostate gland—urinary bladder cancer	0.000524	0.0108	CbGeAlD
Naloxone—CYP3A4—renal system—urinary bladder cancer	0.000504	0.0104	CbGeAlD
Naloxone—Irritability—Fluorouracil—urinary bladder cancer	0.000497	0.00771	CcSEcCtD
Naloxone—ALB—lymph node—urinary bladder cancer	0.000496	0.0103	CbGeAlD
Naloxone—Cardiac arrest—Fluorouracil—urinary bladder cancer	0.000496	0.00768	CcSEcCtD
Naloxone—Body temperature increased—Mitomycin—urinary bladder cancer	0.000487	0.00755	CcSEcCtD
Naloxone—Irritability—Cisplatin—urinary bladder cancer	0.000472	0.00731	CcSEcCtD
Naloxone—Nasopharyngitis—Fluorouracil—urinary bladder cancer	0.000466	0.00722	CcSEcCtD
Naloxone—ABCB1—seminal vesicle—urinary bladder cancer	0.000443	0.00916	CbGeAlD
Naloxone—Asthenia—Mitomycin—urinary bladder cancer	0.000442	0.00685	CcSEcCtD
Naloxone—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.000442	0.00685	CcSEcCtD
Naloxone—Hallucination—Thiotepa—urinary bladder cancer	0.000434	0.00672	CcSEcCtD
Naloxone—Cardiac arrest—Etoposide—urinary bladder cancer	0.00043	0.00667	CcSEcCtD
Naloxone—ESR1—lymph node—urinary bladder cancer	0.000423	0.00876	CbGeAlD
Naloxone—Diarrhoea—Mitomycin—urinary bladder cancer	0.000421	0.00653	CcSEcCtD
Naloxone—Cardiac disorder—Thiotepa—urinary bladder cancer	0.000405	0.00627	CcSEcCtD
Naloxone—CYP3A4—female reproductive system—urinary bladder cancer	0.000404	0.00835	CbGeAlD
Naloxone—Angiopathy—Thiotepa—urinary bladder cancer	0.000396	0.00613	CcSEcCtD
Naloxone—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.000393	0.00609	CcSEcCtD
Naloxone—Sweating—Gemcitabine—urinary bladder cancer	0.000392	0.00607	CcSEcCtD
Naloxone—Vomiting—Mitomycin—urinary bladder cancer	0.000392	0.00607	CcSEcCtD
Naloxone—Chills—Thiotepa—urinary bladder cancer	0.000391	0.00606	CcSEcCtD
Naloxone—ABCB1—epithelium—urinary bladder cancer	0.000385	0.00796	CbGeAlD
Naloxone—Mental disorder—Thiotepa—urinary bladder cancer	0.000382	0.00592	CcSEcCtD
Naloxone—Tension—Thiotepa—urinary bladder cancer	0.000372	0.00577	CcSEcCtD
Naloxone—Nervousness—Thiotepa—urinary bladder cancer	0.000369	0.00571	CcSEcCtD
Naloxone—Nausea—Mitomycin—urinary bladder cancer	0.000366	0.00567	CcSEcCtD
Naloxone—ABCB1—renal system—urinary bladder cancer	0.000357	0.00738	CbGeAlD
Naloxone—ABCB1—urethra—urinary bladder cancer	0.000351	0.00725	CbGeAlD
Naloxone—Ventricular tachycardia—Epirubicin—urinary bladder cancer	0.00035	0.00542	CcSEcCtD
Naloxone—Agitation—Thiotepa—urinary bladder cancer	0.000349	0.0054	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—urinary bladder cancer	0.000347	0.00539	CcSEcCtD
Naloxone—Coma—Methotrexate—urinary bladder cancer	0.000341	0.00529	CcSEcCtD
Naloxone—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.00034	0.00527	CcSEcCtD
Naloxone—Angiopathy—Gemcitabine—urinary bladder cancer	0.000333	0.00516	CcSEcCtD
Naloxone—Pulmonary oedema—Methotrexate—urinary bladder cancer	0.000332	0.00515	CcSEcCtD
Naloxone—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.00033	0.00512	CcSEcCtD
Naloxone—Chills—Gemcitabine—urinary bladder cancer	0.000329	0.0051	CcSEcCtD
Naloxone—Convulsion—Thiotepa—urinary bladder cancer	0.000329	0.0051	CcSEcCtD
Naloxone—Hypertension—Thiotepa—urinary bladder cancer	0.000328	0.00508	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—urinary bladder cancer	0.000323	0.00501	CcSEcCtD
Naloxone—Injection site reaction—Doxorubicin—urinary bladder cancer	0.000322	0.00498	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000321	0.00497	CcSEcCtD
Naloxone—Coma—Epirubicin—urinary bladder cancer	0.000319	0.00495	CcSEcCtD
Naloxone—Flushing—Cisplatin—urinary bladder cancer	0.000317	0.00492	CcSEcCtD
Naloxone—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000317	0.00492	CcSEcCtD
Naloxone—Pulmonary oedema—Epirubicin—urinary bladder cancer	0.000311	0.00482	CcSEcCtD
Naloxone—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000308	0.00477	CcSEcCtD
Naloxone—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000304	0.00471	CcSEcCtD
Naloxone—Tachycardia—Thiotepa—urinary bladder cancer	0.000302	0.00468	CcSEcCtD
Naloxone—Skin disorder—Thiotepa—urinary bladder cancer	0.000301	0.00466	CcSEcCtD
Naloxone—Coma—Doxorubicin—urinary bladder cancer	0.000296	0.00458	CcSEcCtD
Naloxone—Cardiac disorder—Etoposide—urinary bladder cancer	0.000291	0.0045	CcSEcCtD
Naloxone—Flushing—Etoposide—urinary bladder cancer	0.000291	0.0045	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—urinary bladder cancer	0.000288	0.00446	CcSEcCtD
Naloxone—ABCB1—female reproductive system—urinary bladder cancer	0.000286	0.00591	CbGeAlD
Naloxone—Angiopathy—Etoposide—urinary bladder cancer	0.000284	0.0044	CcSEcCtD
Naloxone—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000282	0.00437	CcSEcCtD
Naloxone—Chills—Etoposide—urinary bladder cancer	0.000281	0.00435	CcSEcCtD
Naloxone—Tremor—Cisplatin—urinary bladder cancer	0.000279	0.00432	CcSEcCtD
Naloxone—Paraesthesia—Thiotepa—urinary bladder cancer	0.000278	0.00431	CcSEcCtD
Naloxone—Hypertension—Gemcitabine—urinary bladder cancer	0.000276	0.00427	CcSEcCtD
Naloxone—Convulsion—Fluorouracil—urinary bladder cancer	0.000272	0.00421	CcSEcCtD
Naloxone—Hot flush—Epirubicin—urinary bladder cancer	0.000271	0.0042	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00027	0.00418	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—urinary bladder cancer	0.000269	0.00417	CcSEcCtD
Naloxone—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000267	0.00414	CcSEcCtD
Naloxone—Pain—Thiotepa—urinary bladder cancer	0.000265	0.0041	CcSEcCtD
Naloxone—Irritability—Methotrexate—urinary bladder cancer	0.000259	0.00401	CcSEcCtD
Naloxone—ABCB1—vagina—urinary bladder cancer	0.000259	0.00535	CbGeAlD
Naloxone—Convulsion—Cisplatin—urinary bladder cancer	0.000258	0.004	CcSEcCtD
Naloxone—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000255	0.00396	CcSEcCtD
Naloxone—Skin disorder—Gemcitabine—urinary bladder cancer	0.000253	0.00392	CcSEcCtD
Naloxone—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000252	0.0039	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000252	0.0039	CcSEcCtD
Naloxone—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000251	0.00389	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—urinary bladder cancer	0.000251	0.00389	CcSEcCtD
Naloxone—Tachycardia—Fluorouracil—urinary bladder cancer	0.00025	0.00387	CcSEcCtD
Naloxone—Menopausal symptoms—Doxorubicin—urinary bladder cancer	0.000249	0.00386	CcSEcCtD
Naloxone—Abdominal pain—Thiotepa—urinary bladder cancer	0.000245	0.00379	CcSEcCtD
Naloxone—Body temperature increased—Thiotepa—urinary bladder cancer	0.000245	0.00379	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—urinary bladder cancer	0.000241	0.00374	CcSEcCtD
Naloxone—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000238	0.00369	CcSEcCtD
Naloxone—Tachycardia—Cisplatin—urinary bladder cancer	0.000237	0.00367	CcSEcCtD
Naloxone—Convulsion—Etoposide—urinary bladder cancer	0.000236	0.00366	CcSEcCtD
Naloxone—Skin disorder—Cisplatin—urinary bladder cancer	0.000236	0.00366	CcSEcCtD
Naloxone—Hypertension—Etoposide—urinary bladder cancer	0.000235	0.00365	CcSEcCtD
Naloxone—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000235	0.00364	CcSEcCtD
Naloxone—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000234	0.00363	CcSEcCtD
Naloxone—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000232	0.0036	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00023	0.00357	CcSEcCtD
Naloxone—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00023	0.00356	CcSEcCtD
Naloxone—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000228	0.00354	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000227	0.00352	CcSEcCtD
Naloxone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000225	0.00349	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000223	0.00346	CcSEcCtD
Naloxone—Pain—Gemcitabine—urinary bladder cancer	0.000223	0.00345	CcSEcCtD
Naloxone—Asthenia—Thiotepa—urinary bladder cancer	0.000222	0.00344	CcSEcCtD
Naloxone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000221	0.00343	CcSEcCtD
Naloxone—Pain—Fluorouracil—urinary bladder cancer	0.000219	0.00339	CcSEcCtD
Naloxone—Paraesthesia—Cisplatin—urinary bladder cancer	0.000218	0.00338	CcSEcCtD
Naloxone—Tachycardia—Etoposide—urinary bladder cancer	0.000217	0.00337	CcSEcCtD
Naloxone—Dyspnoea—Cisplatin—urinary bladder cancer	0.000216	0.00336	CcSEcCtD
Naloxone—Skin disorder—Etoposide—urinary bladder cancer	0.000216	0.00335	CcSEcCtD
Naloxone—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000215	0.00333	CcSEcCtD
Naloxone—Diarrhoea—Thiotepa—urinary bladder cancer	0.000212	0.00328	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00021	0.00325	CcSEcCtD
Naloxone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00021	0.00325	CcSEcCtD
Naloxone—Depression—Methotrexate—urinary bladder cancer	0.000208	0.00323	CcSEcCtD
Naloxone—Pain—Cisplatin—urinary bladder cancer	0.000208	0.00322	CcSEcCtD
Naloxone—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000206	0.00319	CcSEcCtD
Naloxone—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000202	0.00314	CcSEcCtD
Naloxone—Sweating—Methotrexate—urinary bladder cancer	0.0002	0.0031	CcSEcCtD
Naloxone—Paraesthesia—Etoposide—urinary bladder cancer	0.0002	0.0031	CcSEcCtD
Naloxone—Dyspnoea—Etoposide—urinary bladder cancer	0.000198	0.00307	CcSEcCtD
Naloxone—Vomiting—Thiotepa—urinary bladder cancer	0.000197	0.00305	CcSEcCtD
Naloxone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000192	0.00298	CcSEcCtD
Naloxone—Body temperature increased—Cisplatin—urinary bladder cancer	0.000192	0.00298	CcSEcCtD
Naloxone—Pain—Etoposide—urinary bladder cancer	0.00019	0.00295	CcSEcCtD
Naloxone—Sweating—Epirubicin—urinary bladder cancer	0.000187	0.00291	CcSEcCtD
Naloxone—Asthenia—Gemcitabine—urinary bladder cancer	0.000187	0.0029	CcSEcCtD
Naloxone—Nausea—Thiotepa—urinary bladder cancer	0.000184	0.00285	CcSEcCtD
Naloxone—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000178	0.00276	CcSEcCtD
Naloxone—Abdominal pain—Etoposide—urinary bladder cancer	0.000176	0.00273	CcSEcCtD
Naloxone—Body temperature increased—Etoposide—urinary bladder cancer	0.000176	0.00273	CcSEcCtD
Naloxone—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000175	0.00272	CcSEcCtD
Naloxone—Asthenia—Cisplatin—urinary bladder cancer	0.000174	0.0027	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000174	0.0027	CcSEcCtD
Naloxone—Sweating—Doxorubicin—urinary bladder cancer	0.000173	0.00269	CcSEcCtD
Naloxone—Angiopathy—Methotrexate—urinary bladder cancer	0.00017	0.00264	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000169	0.00262	CcSEcCtD
Naloxone—Chills—Methotrexate—urinary bladder cancer	0.000168	0.00261	CcSEcCtD
Naloxone—ABCB1—lymph node—urinary bladder cancer	0.000167	0.00346	CbGeAlD
Naloxone—Diarrhoea—Cisplatin—urinary bladder cancer	0.000166	0.00258	CcSEcCtD
Naloxone—Vomiting—Gemcitabine—urinary bladder cancer	0.000166	0.00257	CcSEcCtD
Naloxone—Mental disorder—Methotrexate—urinary bladder cancer	0.000164	0.00255	CcSEcCtD
Naloxone—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000163	0.00252	CcSEcCtD
Naloxone—Flushing—Epirubicin—urinary bladder cancer	0.000163	0.00252	CcSEcCtD
Naloxone—Vomiting—Fluorouracil—urinary bladder cancer	0.000163	0.00252	CcSEcCtD
Naloxone—Asthenia—Etoposide—urinary bladder cancer	0.00016	0.00247	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—urinary bladder cancer	0.000159	0.00247	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000158	0.00245	CcSEcCtD
Naloxone—Chills—Epirubicin—urinary bladder cancer	0.000157	0.00244	CcSEcCtD
Naloxone—Nausea—Gemcitabine—urinary bladder cancer	0.000155	0.0024	CcSEcCtD
Naloxone—Vomiting—Cisplatin—urinary bladder cancer	0.000154	0.00239	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—urinary bladder cancer	0.000154	0.00238	CcSEcCtD
Naloxone—Diarrhoea—Etoposide—urinary bladder cancer	0.000152	0.00236	CcSEcCtD
Naloxone—Nausea—Fluorouracil—urinary bladder cancer	0.000152	0.00236	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000151	0.00234	CcSEcCtD
Naloxone—Flushing—Doxorubicin—urinary bladder cancer	0.000151	0.00234	CcSEcCtD
Naloxone—Tension—Epirubicin—urinary bladder cancer	0.00015	0.00232	CcSEcCtD
Naloxone—Nervousness—Epirubicin—urinary bladder cancer	0.000148	0.0023	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—urinary bladder cancer	0.000147	0.00228	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000146	0.00227	CcSEcCtD
Naloxone—Chills—Doxorubicin—urinary bladder cancer	0.000146	0.00226	CcSEcCtD
Naloxone—Nausea—Cisplatin—urinary bladder cancer	0.000144	0.00224	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000142	0.00221	CcSEcCtD
Naloxone—Convulsion—Methotrexate—urinary bladder cancer	0.000141	0.00219	CcSEcCtD
Naloxone—Vomiting—Etoposide—urinary bladder cancer	0.000141	0.00219	CcSEcCtD
Naloxone—Agitation—Epirubicin—urinary bladder cancer	0.00014	0.00218	CcSEcCtD
Naloxone—Tension—Doxorubicin—urinary bladder cancer	0.000139	0.00215	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000138	0.00214	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—urinary bladder cancer	0.000137	0.00213	CcSEcCtD
Naloxone—Convulsion—Epirubicin—urinary bladder cancer	0.000132	0.00205	CcSEcCtD
Naloxone—Nausea—Etoposide—urinary bladder cancer	0.000132	0.00205	CcSEcCtD
Naloxone—Hypertension—Epirubicin—urinary bladder cancer	0.000132	0.00204	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000131	0.00203	CcSEcCtD
Naloxone—Agitation—Doxorubicin—urinary bladder cancer	0.00013	0.00201	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—urinary bladder cancer	0.000129	0.00201	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000129	0.002	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000129	0.002	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—urinary bladder cancer	0.000122	0.0019	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000122	0.0019	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—urinary bladder cancer	0.000122	0.00189	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—urinary bladder cancer	0.000122	0.00189	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—urinary bladder cancer	0.000121	0.00188	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000121	0.00187	CcSEcCtD
Naloxone—Paraesthesia—Methotrexate—urinary bladder cancer	0.00012	0.00185	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00012	0.00185	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—urinary bladder cancer	0.000119	0.00184	CcSEcCtD
Naloxone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000115	0.00178	CcSEcCtD
Naloxone—Pain—Methotrexate—urinary bladder cancer	0.000114	0.00177	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000113	0.00175	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—urinary bladder cancer	0.000113	0.00175	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000112	0.00174	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—urinary bladder cancer	0.000112	0.00174	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000112	0.00173	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—urinary bladder cancer	0.000111	0.00172	CcSEcCtD
Naloxone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000108	0.00167	CcSEcCtD
Naloxone—Pain—Epirubicin—urinary bladder cancer	0.000107	0.00165	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—urinary bladder cancer	0.000105	0.00163	CcSEcCtD
Naloxone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000105	0.00163	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000104	0.00161	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000103	0.00159	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	9.96e-05	0.00154	CcSEcCtD
Naloxone—Pain—Doxorubicin—urinary bladder cancer	9.87e-05	0.00153	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—urinary bladder cancer	9.86e-05	0.00153	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—urinary bladder cancer	9.86e-05	0.00153	CcSEcCtD
Naloxone—Asthenia—Methotrexate—urinary bladder cancer	9.56e-05	0.00148	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—urinary bladder cancer	9.12e-05	0.00141	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—urinary bladder cancer	9.12e-05	0.00141	CcSEcCtD
Naloxone—Diarrhoea—Methotrexate—urinary bladder cancer	9.12e-05	0.00141	CcSEcCtD
Naloxone—Asthenia—Epirubicin—urinary bladder cancer	8.95e-05	0.00139	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—urinary bladder cancer	8.53e-05	0.00132	CcSEcCtD
Naloxone—Vomiting—Methotrexate—urinary bladder cancer	8.47e-05	0.00131	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—urinary bladder cancer	8.28e-05	0.00128	CcSEcCtD
Naloxone—Vomiting—Epirubicin—urinary bladder cancer	7.93e-05	0.00123	CcSEcCtD
Naloxone—Nausea—Methotrexate—urinary bladder cancer	7.92e-05	0.00123	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—urinary bladder cancer	7.89e-05	0.00122	CcSEcCtD
Naloxone—Nausea—Epirubicin—urinary bladder cancer	7.41e-05	0.00115	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—urinary bladder cancer	7.34e-05	0.00114	CcSEcCtD
Naloxone—Nausea—Doxorubicin—urinary bladder cancer	6.85e-05	0.00106	CcSEcCtD
Naloxone—OPRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.39e-05	9.49e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	1.39e-05	9.47e-05	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—MYC—urinary bladder cancer	1.39e-05	9.46e-05	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—HRAS—urinary bladder cancer	1.38e-05	9.43e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—IL2—urinary bladder cancer	1.38e-05	9.42e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.37e-05	9.38e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.36e-05	9.31e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.36e-05	9.28e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—RRM2—urinary bladder cancer	1.35e-05	9.2e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—RRM2—urinary bladder cancer	1.34e-05	9.15e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—ERBB2—urinary bladder cancer	1.33e-05	9.11e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—S100B—urinary bladder cancer	1.33e-05	9.09e-05	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HRAS—urinary bladder cancer	1.33e-05	9.05e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.31e-05	8.95e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—FGFR3—urinary bladder cancer	1.31e-05	8.95e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL2—urinary bladder cancer	1.31e-05	8.94e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—FGFR3—urinary bladder cancer	1.31e-05	8.92e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PTGS2—urinary bladder cancer	1.3e-05	8.91e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.3e-05	8.89e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IGF1—urinary bladder cancer	1.29e-05	8.78e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ESR1—urinary bladder cancer	1.27e-05	8.69e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ESR1—urinary bladder cancer	1.27e-05	8.66e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—RHOA—urinary bladder cancer	1.26e-05	8.62e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.26e-05	8.6e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL2—urinary bladder cancer	1.25e-05	8.55e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TERT—urinary bladder cancer	1.25e-05	8.52e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	1.25e-05	8.52e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ENO2—urinary bladder cancer	1.25e-05	8.52e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—HPGDS—urinary bladder cancer	1.24e-05	8.47e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ENO2—urinary bladder cancer	1.24e-05	8.47e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.24e-05	8.47e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—CDKN1A—urinary bladder cancer	1.24e-05	8.43e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.23e-05	8.42e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PTEN—urinary bladder cancer	1.23e-05	8.41e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.22e-05	8.33e-05	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.21e-05	8.27e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	1.21e-05	8.26e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTT1—urinary bladder cancer	1.2e-05	8.22e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NCOR1—urinary bladder cancer	1.2e-05	8.17e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.19e-05	8.14e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.19e-05	8.12e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.19e-05	8.09e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—S100B—urinary bladder cancer	1.18e-05	8.06e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—RHOA—urinary bladder cancer	1.18e-05	8.04e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EP300—urinary bladder cancer	1.18e-05	8.02e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.17e-05	8.01e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—PPARG—urinary bladder cancer	1.17e-05	7.99e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.17e-05	7.96e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.16e-05	7.91e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—FGFR3—urinary bladder cancer	1.15e-05	7.82e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—SRC—urinary bladder cancer	1.14e-05	7.8e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—CDKN1A—urinary bladder cancer	1.14e-05	7.79e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PTEN—urinary bladder cancer	1.14e-05	7.77e-05	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.13e-05	7.69e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	1.12e-05	7.68e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—CREBBP—urinary bladder cancer	1.12e-05	7.67e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CREBBP—urinary bladder cancer	1.12e-05	7.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ESR1—urinary bladder cancer	1.11e-05	7.6e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CREBBP—urinary bladder cancer	1.11e-05	7.59e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.11e-05	7.56e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IGF1—urinary bladder cancer	1.1e-05	7.52e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IGF1—urinary bladder cancer	1.1e-05	7.5e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—EGFR—urinary bladder cancer	1.1e-05	7.48e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—EGFR—urinary bladder cancer	1.09e-05	7.46e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.09e-05	7.42e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.09e-05	7.42e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EP300—urinary bladder cancer	1.09e-05	7.41e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	1.08e-05	7.37e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NCOR1—urinary bladder cancer	1.06e-05	7.25e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.06e-05	7.23e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—SRC—urinary bladder cancer	1.06e-05	7.2e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	1.06e-05	7.2e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.05e-05	7.2e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—KRAS—urinary bladder cancer	1.04e-05	7.07e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—KRAS—urinary bladder cancer	1.03e-05	7.05e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—RHOA—urinary bladder cancer	1.01e-05	6.89e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RHOA—urinary bladder cancer	1.01e-05	6.87e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.01e-05	6.87e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—urinary bladder cancer	1e-05	6.84e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NQO1—urinary bladder cancer	1e-05	6.83e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—IL2—urinary bladder cancer	9.88e-06	6.74e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.87e-06	6.74e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.76e-06	6.66e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	9.75e-06	6.66e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.71e-06	6.62e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	9.68e-06	6.61e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	9.63e-06	6.57e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	9.58e-06	6.54e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—urinary bladder cancer	9.46e-06	6.46e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MYC—urinary bladder cancer	9.46e-06	6.46e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	9.41e-06	6.42e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TERT—urinary bladder cancer	9.36e-06	6.39e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB2—urinary bladder cancer	9.34e-06	6.38e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB2—urinary bladder cancer	9.32e-06	6.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	9.27e-06	6.33e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—urinary bladder cancer	9.25e-06	6.31e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	9.05e-06	6.18e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—EP300—urinary bladder cancer	8.87e-06	6.05e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—urinary bladder cancer	8.86e-06	6.05e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	8.85e-06	6.04e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—urinary bladder cancer	8.83e-06	6.03e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	8.82e-06	6.02e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—urinary bladder cancer	8.8e-06	6.01e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—urinary bladder cancer	8.78e-06	5.99e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NQO1—urinary bladder cancer	8.76e-06	5.98e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—urinary bladder cancer	8.74e-06	5.96e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—SRC—urinary bladder cancer	8.62e-06	5.89e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGFR3—urinary bladder cancer	8.59e-06	5.86e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.51e-06	5.81e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL2—urinary bladder cancer	8.47e-06	5.78e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.46e-06	5.78e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL2—urinary bladder cancer	8.44e-06	5.76e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	8.39e-06	5.73e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.38e-06	5.72e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—urinary bladder cancer	8.34e-06	5.7e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—urinary bladder cancer	8.26e-06	5.64e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	8.24e-06	5.63e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—urinary bladder cancer	8.23e-06	5.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	8.17e-06	5.58e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	8.14e-06	5.56e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.12e-06	5.54e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	8.1e-06	5.53e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.07e-06	5.51e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—urinary bladder cancer	8.04e-06	5.49e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—urinary bladder cancer	8.02e-06	5.47e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—urinary bladder cancer	7.99e-06	5.45e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.99e-06	5.45e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PTEN—urinary bladder cancer	7.97e-06	5.44e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.96e-06	5.43e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PTEN—urinary bladder cancer	7.94e-06	5.42e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TYMS—urinary bladder cancer	7.8e-06	5.32e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—TYMS—urinary bladder cancer	7.76e-06	5.29e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	7.75e-06	5.29e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	7.71e-06	5.27e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	7.71e-06	5.26e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	7.71e-06	5.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	7.7e-06	5.25e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—urinary bladder cancer	7.67e-06	5.23e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NCOR1—urinary bladder cancer	7.67e-06	5.23e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	7.65e-06	5.22e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EP300—urinary bladder cancer	7.6e-06	5.19e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EP300—urinary bladder cancer	7.58e-06	5.17e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	7.46e-06	5.09e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—urinary bladder cancer	7.43e-06	5.07e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	7.4e-06	5.05e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SRC—urinary bladder cancer	7.39e-06	5.04e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GPX1—urinary bladder cancer	7.38e-06	5.04e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SRC—urinary bladder cancer	7.37e-06	5.03e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—EP300—urinary bladder cancer	7.36e-06	5.02e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GPX1—urinary bladder cancer	7.34e-06	5.01e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	7.31e-06	4.99e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CREBBP—urinary bladder cancer	7.31e-06	4.99e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	7.25e-06	4.95e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.23e-06	4.94e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IGF1—urinary bladder cancer	7.22e-06	4.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	7.22e-06	4.93e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ERCC2—urinary bladder cancer	7.21e-06	4.92e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—urinary bladder cancer	7.14e-06	4.87e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	7.01e-06	4.78e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.98e-06	4.77e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	6.97e-06	4.75e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	6.9e-06	4.71e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	6.81e-06	4.65e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TYMS—urinary bladder cancer	6.8e-06	4.64e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—urinary bladder cancer	6.78e-06	4.63e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	6.72e-06	4.59e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	6.72e-06	4.59e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.7e-06	4.57e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.7e-06	4.57e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—urinary bladder cancer	6.67e-06	4.55e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	6.64e-06	4.53e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—urinary bladder cancer	6.62e-06	4.52e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RHOA—urinary bladder cancer	6.61e-06	4.51e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	6.6e-06	4.51e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	6.55e-06	4.47e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	6.5e-06	4.44e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.5e-06	4.44e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—urinary bladder cancer	6.48e-06	4.42e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	6.46e-06	4.41e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	6.46e-06	4.41e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GPX1—urinary bladder cancer	6.43e-06	4.39e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—urinary bladder cancer	6.34e-06	4.33e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	6.32e-06	4.31e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	6.26e-06	4.27e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—urinary bladder cancer	6.12e-06	4.18e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—urinary bladder cancer	6.12e-06	4.18e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	6.1e-06	4.16e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	6.1e-06	4.16e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—urinary bladder cancer	6.07e-06	4.14e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.94e-06	4.05e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	5.92e-06	4.04e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.9e-06	4.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	5.89e-06	4.02e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—urinary bladder cancer	5.8e-06	3.96e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	5.79e-06	3.95e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	5.66e-06	3.86e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	5.61e-06	3.83e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL2—urinary bladder cancer	5.55e-06	3.79e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARG—urinary bladder cancer	5.53e-06	3.77e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARG—urinary bladder cancer	5.49e-06	3.75e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	5.46e-06	3.73e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—urinary bladder cancer	5.44e-06	3.71e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	5.42e-06	3.7e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—urinary bladder cancer	5.41e-06	3.69e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.4e-06	3.69e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	5.35e-06	3.65e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	5.31e-06	3.62e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CREBBP—urinary bladder cancer	5.28e-06	3.6e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—urinary bladder cancer	5.25e-06	3.58e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.23e-06	3.57e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PTEN—urinary bladder cancer	5.22e-06	3.56e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—urinary bladder cancer	5.2e-06	3.55e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	5.18e-06	3.54e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EP300—urinary bladder cancer	4.98e-06	3.4e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	4.89e-06	3.34e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SRC—urinary bladder cancer	4.84e-06	3.3e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.81e-06	3.29e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	4.78e-06	3.27e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	4.75e-06	3.24e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.62e-06	3.16e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	4.55e-06	3.1e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	4.52e-06	3.09e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.5e-06	3.07e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	4.35e-06	2.97e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—urinary bladder cancer	4.34e-06	2.96e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—urinary bladder cancer	4.32e-06	2.95e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—urinary bladder cancer	4.24e-06	2.9e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.19e-06	2.86e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.14e-06	2.83e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.14e-06	2.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	4.02e-06	2.74e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—urinary bladder cancer	4.01e-06	2.74e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.96e-06	2.71e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.89e-06	2.66e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	3.84e-06	2.62e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTEN—urinary bladder cancer	3.79e-06	2.59e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.79e-06	2.59e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTEN—urinary bladder cancer	3.77e-06	2.57e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.66e-06	2.5e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—EP300—urinary bladder cancer	3.62e-06	2.47e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—EP300—urinary bladder cancer	3.59e-06	2.45e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—urinary bladder cancer	3.56e-06	2.43e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—urinary bladder cancer	3.41e-06	2.33e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.3e-06	2.25e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—EP300—urinary bladder cancer	3.15e-06	2.15e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.97e-06	2.02e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.85e-06	1.94e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.33e-06	1.59e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.03e-06	1.39e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.94e-06	1.32e-05	CbGpPWpGaD
